logo

For the Inventor, By the Inventor

Paris, France

Pharnext


USPTO Granted Patents = 54

% Expired Patents = 50.0



Trademarks = 5

Forward Citations = 209

Loading Chart...
Loading Chart...

17 inventors (with patents filed for the assignee):

goldMedal Daniel Cohen (54 out of 65 patents)

silverMedal Ilya Chumakov (52 out of 85 patents)

bronzeMedal Serguei Nabirochkin (52 out of 52 patents)

4.  Rodolphe Hajj (16 out of 16 patents)

5.  Oxana Guerassimenko (12 out of 13 patents)

6.  Emmanuel Vial (8 out of 14 patents)

7.  Mickael Guedj (6 out of 6 patents)

8.  Aude Milet (3 out of 3 patents)

9.  Klaus-Armin Nave (3 out of 7 patents)

10.  Thomas Prukop (3 out of 3 patents)

11.  Michael Sereda (3 out of 3 patents)

12.  Esther Graudens (2 out of 2 patents)

13.  Nathalie Cholet (2 out of 2 patents)

14.  Viviane Bertrand (2 out of 2 patents)

15.  Mickaël Guedj (2 out of 2 patents)


Core Competencies:
CMT Disease
Alzheimer's Disease
Neurological Disorders
Diabetes Management
Angiogenesis Modulation
Synapse Function
Combination Therapy
Nootropic Compositions
Biomarkers Detection
Parkinson's Disease
Therapeutic Approaches
Cerebral Ischemia

54 patents:

1. 12226413 - Early treatment of CMT disease (2025-02-18),
2. 11672796 - Compositions for treating CMT and related disorders (2023-06-13),
3. 11576908 - Compositions for treating CMT and related disorders (2023-02-14),
4. 11291670 - Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of angiogenesis (2022-04-05),
5. 10940147 - Early treatment of CMT disease (2021-03-09),
6. 10905686 - Compositions for treating CMT and related disorders (2021-02-02),
7. 10905672 - Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders (2021-02-02),
8. 10874644 - Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of synapse function (2020-12-29),
9. 10849851 - Stable oral solutions for combined API (2020-12-01),
10. 10799499 - Combinatorial therapies of neurological disorders (2020-10-13),
11. 10736876 - Idalopirdine-based combinatorial therapies of Alzheimer's disease (2020-08-11),
12. 10682342 - Compositions for treating amyotrophic lateral sclerosis (2020-06-16),
13. 10617689 - Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level (2020-04-14),
14. 10596160 - Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level (2020-03-24),
15. 10583135 - Compositions for treating CMT and related disorders (2020-03-10),
Pharnext is a biopharmaceutical company based in Paris, specializing in the development of innovative therapies for neurological disorders. The company focuses on addressing conditions such as Charcot-Marie-Tooth disease and Alzheimer's disease through advanced research in combination therapies and nootropic compositions. Pharnext's expertise extends to diabetes management and the modulation of angiogenesis and synapse function, positioning it at the forefront of neurological health advancements.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Pharnext
54 Patents

#124 in Paris

#448 in France

#13,100 in the World

Paris, FR
Paris, France

Pharnext

Forward Citations = 209

17 inventors:

goldMedal Daniel Cohen (54 out of 65 patents)

silverMedal Ilya Chumakov (52 out of 85 patents)

bronzeMedal Serguei Nabirochkin (52 out of 52 patents)

4.  Rodolphe Hajj (16 out of 16 patents)

5.  Oxana Guerassimenko (12 out of 13 patents)

Please report any incorrect information to [email protected]
Loading…